Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
1.Establish population pharmacokinetic (PPK) models of each anti-tuberculsis drug in children by nonlinear mixed effect modeling (NONMEM).
- At different timepoint after anti-tuberculsis drug administration, plasma samples of 100 children will be collected from neonatal intensive care unit (NICU) and pneumology department for each drug. The clinical information includes demography, medication, concentration data, blood biochemical parameters and so on .
- Plasma samples will be tested by high performance liquid chromatography (HPLC).
- PPK models of anti-tuberculsis drug will be established by NONMEM program.
- The reliability and stability of the PPK model will be evaluated by 1000 times of Bootstrap procedure and normalized predictive distribution error (NPDE).
2.Evaluation of the clinical feasibility and safety of individualized dosing.
- According the results of PPK models, the investigators will use dosages recommended in models to cure TB children in prospective studies. For anti-tuberculsis drug, 50 children will be collected.
- The investigators will compare the therapeutic effects and safety between children with conventional therapies and children with individualized therapies, including proportions of children with effective drug concentration, improvement speed of of children, liver and kidney functions of of children, adverse reactions of drugs and so on.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: A-Dong Shen, Master
- Phone Number: +86-010-59616898
- Email: shenad16@hotmail.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Beijing Children's Hospital of Capital Medical University
-
Contact:
- Adong Shen, Master
- Phone Number: 13370115087
- Email: shenad16@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Children (0-18 years old) with anti-tuberculosis therapy against TB.
- The anti-tuberculsis therapy includes drugs commonly used in children infectious diseases
- Informed consent signed by the parents and/or guardians.
Exclusion Criteria:
- Anti-tuberculosis drugs aren't involved in the therapies of children.
- It is unable to provide complete medical records or the current condition cannot accept the study process.
- Patients are allergic to anti-tuberculsis drugs.
- Parents and/or guardians do not agree to participate in this study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
maximum concentration (Cmax)
Time Frame: up to 4 weeks
|
Cmax is a term used in pharmacokinetics refers to the maximum (or peak) serum
|
up to 4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
time to achieve maximum concentration (Tmax)
Time Frame: up to 4 weeks
|
Tmax is the term used in pharmacokinetics to describe the time at which the Cmax
|
up to 4 weeks
|
|
absorption rate constant (ka)
Time Frame: up to 4 weeks
|
Ka is the rate constant of drug absorption.
|
up to 4 weeks
|
|
elimination rate constant (kel)
Time Frame: up to 4 weeks
|
The elimination rate constant is a value used in pharmacokinetics to describe the rate at which a drug is removed from the system.
|
up to 4 weeks
|
|
half-life (t1/2)
Time Frame: up to 4 weeks
|
Half-life is the time required for a quantity to reduce to half its initial value.
|
up to 4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: A-Dong Shen, Master, Beijing Children's Hospital of Capital Medical University
- Study Director: Yu-Jie Qi, Master, Beijing Children's Hospital of Capital Medical University
- Study Director: Wei Zhao, Doctor, Children's Hospital of Hebei Province;Shandong Provincial Qianfoshan Hospital
Publications and helpful links
General Publications
- Jacqz-Aigrain E, Leroux S, Zhao W, van den Anker JN, Sharland M. How to use vancomycin optimally in neonates: remaining questions. Expert Rev Clin Pharmacol. 2015;8(5):635-48. doi: 10.1586/17512433.2015.1060124. Epub 2015 Aug 4.
- Ho PL, Lo PY, Chow KH, Lau EH, Lai EL, Cheng VC, Kao RY. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect. 2010 Feb;60(2):140-5. doi: 10.1016/j.jinf.2009.11.011. Epub 2009 Dec 2.
- Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003 Sep 18;349(12):1157-67. doi: 10.1056/NEJMra035092. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antimetabolites
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Hypolipidemic Agents
- Lipid Regulating Agents
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Leprostatic Agents
- Protein Synthesis Inhibitors
- Pharmaceutical Solutions
- Antibiotics, Antitubercular
- Cytochrome P-450 CYP1A2 Inhibitors
- beta-Lactamase Inhibitors
- Ophthalmic Solutions
- Anti-Infective Agents, Urinary
- Renal Agents
- Fatty Acid Synthesis Inhibitors
- Moxifloxacin
- Imipenem
- Amoxicillin
- Levofloxacin
- Gatifloxacin
- Cycloserine
- Bedaquiline
- Clavulanic Acid
- Amoxicillin-Potassium Clavulanate Combination
- Amikacin
- Isoniazid
- Pyrazinamide
- Ethambutol
- Clofazimine
- Aminosalicylic Acid
- Streptomycin
- Ethionamide
- Kanamycin
- Capreomycin
- Thioacetazone
- Antitubercular Agents
Other Study ID Numbers
Other Study ID Numbers
- BCH_PPK003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.